

Special Issue

Novel and Emerging Biomarkers in Neurodegenerative Disorders

Message from the Guest Editors

The integration of multiple omics approaches with biofluid- and imaging-based biomarkers enables insights to be gained into the metabolic processes characterizing specific stages of the investigated diseases, and how they are affected by certain treatments. From a clinical perspective, this knowledge is particularly crucial not only for the development of strategies for the treatment and prevention of these pathologies, but also for the optimization of the current diagnostic frameworks and clinical management of patients.

This Special Issue aims to include preclinical, population-based, and clinical studies that investigate the biological processes underlying neurodegenerative diseases in order to identify novel biomarkers. Investigations integrating various technologies with one or more omics approaches are particularly encouraged. Methodological articles presenting novel strategies for biomarker discovery and validation are also highly welcome.

Guest Editors

Dr. Giuseppe Barisano


Department of Neurosurgery, Stanford University, Stanford, CA, USA

Dr. Silvia Alboni

Department of Life Sciences, University of Modena and Reggio Emilia, 41121 Modena, Italy

Deadline for manuscript submissions

closed (31 January 2024)



Metabolites

an Open Access Journal
by MDPI

Impact Factor 3.7
CiteScore 6.9
Indexed in PubMed



mdpi.com/si/179465

Metabolites
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
metabolites@mdpi.com

[mdpi.com/journal/
metabolites](https://mdpi.com/journal/metabolites)





Metabolites

an Open Access Journal
by MDPI

Impact Factor 3.7
CiteScore 6.9
Indexed in PubMed



[mdpi.com/journal/
metabolites](https://mdpi.com/journal/metabolites)



About the Journal

Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

Editor-in-Chief

Dr. Amedeo Lonardo

Internal Medicine, Ospedale Civile di Baggiovara, Azienda Ospedaliero-Universitaria, 41126 Modena, Italy

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q2 (Endocrinology, Diabetes and Metabolism)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.4 days after submission; acceptance to publication is undertaken in 3.6 days (median values for papers published in this journal in the first half of 2025).